fifty-six patients with t1-t3 and t2-t3 n0 medial lesions of breast carcinoma were randomized after modified radical mastectomy to receive either cytoxan , methotrexate , 5-fluorouracil ( 5-fu ) ( cmf ) chemotherapy for 1 year ( group a ) or cmf for 1 year and postoperative radiation therapy ( group b ) .
C0025677
methotrexate
C0950521
cmf